Skip to main content
. 2017 Sep 9;24(1):1262–1272. doi: 10.1080/10717544.2017.1373163

Figure 3.

Figure 3.

The in vitro antitumor activity of nanoformulations in MCF-7 and MDA-MB-231 breast cancer cells. The cells were treated with formulations (0.1–10 µg/mL) for 24 h. The cell proliferation was evaluated by MTT assay. Data are presented as mean ± S.D (n = 6).*p < .05, **p < .01, ***p < .001.